Journal article
Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate
S Lekawanvijit, AR Kompa, M Manabe, BH Wang, RG Langham, F Nishijima, DJ Kelly, H Krum
Plos One | Published : 2012
Abstract
Cardiovascular death commonly occurs in patients with chronic kidney disease. Indoxyl sulfate (IS), a uremic toxin, has been demonstrated in vitro as a contributory factor in cardiac fibrosis, a typical pathological finding in uremic cardiomyopathy. This study aimed to determine if cardiac fibrosis is reversible by lowering serum IS levels using an oral charcoal adsorbent, AST-120. Subtotal-nephrectomized (5/6-STNx) Sprague-Dawley rats were randomized to receive either AST-120 (AST-120, n = 13) or no treatment (vehicle, n = 17) for 12 weeks. Sham operated rats (n = 12) were used as controls. Early left ventricular (LV) diastolic dysfunction was demonstrated by an increase in peak velocity of..
View full abstractRelated Projects (2)
Grants
Awarded by Seventh Framework Programme
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council [Program Grant #334008 and #546272]. The URL of the funder's website is http://www.nhmrc.gov.au. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.The authors would like to acknowledge the technical support of Ms Mariana Pacheco and Ms Jemma Court for the animal studies, Ms Alison Cox for assistance with the Cobas assay, Dr Yuan Zhang for assistance with cardiac fibrosis analysis. S.L. is a recipient of a scholarship from the 'Prince Doctor' Fund, Chiang Mai University, Thailand, under the Royal Patronage of Her Royal Highness Princess Galyanivadhana.